The effect of IL-28A on human cord blood CD4+ T cells

Immunopharmacology and Immunotoxicology

Volumn 32, Issue 2, 2010, Pages 339-347

  Arasteh, Javad ^a   Ebtekar, Masoumeh ^a   Pourpak, Zahra ^b   Pourfatollah, Ali Akbar ^a   Hassan, Zuhair Mohammad ^a   Farahmandian, Tahereh ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CD4+ T cell; Cord blood; Foxp3; Interleukin 28A; Regulatory T cells

Indexed keywords

CD3 ANTIBODY; CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 28A; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; NEWBORN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; FETAL BLOOD; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INFANT, NEWBORN; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77952218743     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970903317445     Document Type: Article

References (41)

1. Laughlin MJ, Eapen M, Rubinstein P, Wagner J.E, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351(22):2265-2275.
2. Koh LP, Chao NJ. Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens. Biol Blood Marrow Transplant 2004;10(1):1-22.
3. Gluckman, E, Rocha, V, Boyer-Chammard, A, Locatelli, F, Arcese, W, Pasquini, R, et al.Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337(6):373-381.
4. Petropoulos D, Chan KW. Umbilical cord blood transplantation. Curr Oncol Rep 2005;7(6):406-409.
5. Fruchtman S.Stem cell transplantation. Mt. Sinai J Med 2003;70(3):166-170.
6. Han, P, Hodge, G, Story, C, Xu X. Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation. Br J Haematol 1995;89(4):733-740.
7. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3(3):199-210.
8. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184(2):387-396.
9. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen ML, Shah NK, , et al. IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunol 2003;4(1):69-77.
10. Sheppard P, Kindsvogel W, Xu WF, Henderson K, Schlutsmeyer S, Whitmore TE, et al.,?et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunol 2003;4(1):63-68.
11. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambda s exhibit antitumor activity against B16 melanoma. Cancer Res 2006;66(8): 4468-4477.
12. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004;34(3):796-805.
13. Dumoutier, L, Lejeune, D.; Hor S, Fickenscher H, Renauld JC. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J2003;370:391-396.
14. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukocyte Biol 2004;76(2): 314-321.
15. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and-29: Comparison with type I interferons. Cytokine 2005;31(2):109-118.
16. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, et al.Human interferon lambda-1 (IFN-lambda 1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007;8(3): 254-261. (Pubitemid 46679436)
17. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1-similarities with type I interferon signaling. J BiologChem 2004;279(31):32269-32274.
18. Langer JA, Cutrone EC, Kotenko S. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Revs 2004;15(1):33-48.
19. Brand, S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte J.M, Diebold J, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005;289(5):G960-G968.
20. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, Spottl G, et al. Novel interferon-lambda s induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Comms 2006;344(4):1334-1341.
21. Ank N, West H, Paludan, SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006;26(6):373-379.
22. Melchjorsen J, Siren J, Julkunen K, Paludan SR, Matikainen S. Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappa B and IRF-3. J Gen Virol 2006;87:1099-1108.
23. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J Immunol 2006;176(12):7686-7694.
24. Chi B, Dickensheets HL, Spann KM, Alston MA, Luongo C, Dumoutier L, et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 2006;80(10):5032-5040.
25. Mennechet FJD, Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of Foxp3-expressing suppressor T cells. Blood 2006;107(11):4417-4423.
26. de Waal MR,; Haanen J, Spits H, Roncarolo MG, Te VA, Figdor C et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174(4):915-924.
27. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174(5):1209-1220.
28. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996;184(1):19-29. (Pubitemid 26247211)
29. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25(high) regulatory cells in human peripheral blood. J Immunol 2001;167(3):1245-1253.
30. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 2005;22(3):329-341.
31. Koenen HJPM, Fasse E, Joosten I. CD27/CFSE based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. Am J Transplant 2005;5:361.
32. Walker MR, Kasprowicz DJ,; Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler, SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4(+)CD25(-) T cells. J Clin Invest 2003;112(9):1437-1443.
33. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, et al. Crucial role of FOXP3 in the development and function of human CD25(+)CD4(+) regulatory T cells. Intern Immunol 2004;16 (11):1643-1656.
34. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif 2008;41(6):960-979.
35. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Intern Immunol 2007;19(4):345-354.
36. Nelson BH. Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol1998;70:1-81.
37. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006;25(2):195-201.
38. Tran D.Q, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110(8):2983-2990.
39. Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM. FOXP3(+)CD4(+)CD25(+) adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E-2-dependent mechanism. J Immunol 2006;177(1): 246-254.
40. Mahic M, Yaqub S, Bryn T, Henjum K, Eide DM, Torgersen KM, Aandahl, EM, Tasken, K. Differentiation of naive CD4+ T cells into CD4+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. J Leukocyte Biol 2008;83(5):1111-1117.
41. Walker MR, Carson BD, Ziegler SF, Nepom GT, Buckner JH. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25-cells. Proc Natl Acad Sci 2005; 102(11):4103-4108.